Zhoulei Li
Institute of Helmholtz Center Munich, Germany
Title: Early prediction of response to anti-cancer therapy using molecular Imaging PET/CT
Biography
Biography: Zhoulei Li
Abstract
The prognosis of relapsed or refractory aggressive lymphoma is poor. The huge variety of currently evolving targeted
treatment approaches would benefit from tools for early prediction of response or resistance. Molecular imaging is
recently recognized as a tool that can improve every facet of cancer care. PET images biochemical or physiologic phenomena
in comparison with computed tomography (CT) or magnetic resonance imaging (MRI), which show anatomic details. PET
imaging would predict areas of abnormal metabolic behaviour of cancers in vivo, and the addition of CT imaging underlines
the site of malignancy. More accurate andprecise interpretation of cancer lesions can therefore be performed by PET/CT
imaging than PET or CT imaging alone. We used various lymphoma cell lines (ALCL, DLBCL, MCL, Myc-induced murine
lymphoma etc.) to evaluate therapeutic effect of different anti-cancer drugs in vitro by molecular biological and biochemical
methods. Micro-FDG- and/or FLT-positron emission tomography (PET) or PET/CT imaging studies were carried out with the
suitable xenograft or transgenic mouse models to assess early treatment response to anti-cancer therapy in vivo. Interestingly,
we detected a significant reduction of FLT-uptake in ALCL bearing animals using targeted drug therapy compared with
baseline as early as 2 days after initiation of targeted therapy. Immunostaining showed a decrease in Ki-67 and an increase
in cleaved caspase-3 staining. Additionally, the detection of therapeutic response of other aggressive cancer was proved to be
highly correlated with other in vito and in vivo data, suggests that PET/CT is a suitable method for detection of therapeutic
respons on cancer.